ES2111167T3 - Compuestos peptidicos. - Google Patents

Compuestos peptidicos.

Info

Publication number
ES2111167T3
ES2111167T3 ES93917902T ES93917902T ES2111167T3 ES 2111167 T3 ES2111167 T3 ES 2111167T3 ES 93917902 T ES93917902 T ES 93917902T ES 93917902 T ES93917902 T ES 93917902T ES 2111167 T3 ES2111167 T3 ES 2111167T3
Authority
ES
Spain
Prior art keywords
peptides
peptide
synthesis
steps
presented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93917902T
Other languages
English (en)
Inventor
Istvan Toth
William Anthony Gibbons
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University College London
Original Assignee
University College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University College London filed Critical University College London
Application granted granted Critical
Publication of ES2111167T3 publication Critical patent/ES2111167T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LOS PEPTIDOS SINTETICOS SE UTILIZAN MUCHO PARA GENERAR ANTICUERPOS. PARA INDUCIR UN ALTO GRADO DE RESPUESTA A LOS ANTICUERPOS SE SABE QUE CONJUGANDO EL PEPTIDO A UNA PROTEINA PORTADORA (EJ. KLH, BSA) O INCORPORANDOLO EN UNA POLILISINA SE FORMA UN PEPTIDO ANTIGENICO MULTIPLE. SE PUEDEN FORMAR ENLACES BASADOS EN ACIDOS GRASOS. SEGUN LA INVENCION SE PRESENTA UN NUEVO AMINOACIDO LIPIDICO BASADO EN UN SISTEMA DE ENLACE QUE PUEDE AUMENTAR AL MAXIMO LA ANTIGENICIDAD DE UN PEPTIDO SINTETICO CORTO. ESTOS NUEVOS COMPUESTOS SE BASAN POR COMPLETO EN PEPTIDOS Y POR TANTO SE PUEDEN PRODUCIR AUTOMATICAMENTE MEDIANTE ALGUNAS SINTESIS DE PEPTIDOS POR PASOS, PREFERENTEMENTE MEDIANTE UNA SINTESIS DE PEPTIDOS POR PASOS EN FASE SOLIDA. EN LA INVENCION TAMBIEN SE PRESENTA TAL PROCESO.
ES93917902T 1992-07-24 1993-07-23 Compuestos peptidicos. Expired - Lifetime ES2111167T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929215780A GB9215780D0 (en) 1992-07-24 1992-07-24 Peptide compounds

Publications (1)

Publication Number Publication Date
ES2111167T3 true ES2111167T3 (es) 1998-03-01

Family

ID=10719254

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93917902T Expired - Lifetime ES2111167T3 (es) 1992-07-24 1993-07-23 Compuestos peptidicos.

Country Status (7)

Country Link
US (1) US5882645A (es)
EP (1) EP0652896B1 (es)
AU (1) AU4715493A (es)
DE (1) DE69315842T2 (es)
ES (1) ES2111167T3 (es)
GB (1) GB9215780D0 (es)
WO (1) WO1994002506A1 (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0670728A4 (en) * 1992-11-12 1996-04-17 Molecular Dynamics Inc PIPTIDE-BASED LIPOPHILE-BASED CARRIERS FOR TARGETED MEDICINE ADMINISTRATION USING A RATIONAL MEDICINE-BINDING DESIGN.
AUPM885194A0 (en) * 1994-10-14 1994-11-10 Council Of The Queensland Institute Of Medical Research, The Synthetic peptides and vaccines comprising same
WO1997038011A1 (en) * 1996-04-03 1997-10-16 Pepresearch A/S Non-dendritic backbone peptide carrier
EP0884327B1 (en) 1997-06-11 2001-03-14 The School Of Pharmacy, University Of London Dendritic lysine-based polypeptides for targeted drug delivery
US6958148B1 (en) 1998-01-20 2005-10-25 Pericor Science, Inc. Linkage of agents to body tissue using microparticles and transglutaminase
US6919076B1 (en) 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
US7081495B1 (en) 1998-09-23 2006-07-25 School Of Pharmacy, University Of London Cationic compounds and their use as macro molecular carriers
DE69912827T2 (de) * 1998-09-29 2004-10-21 Loke Diagnostics Aps Aarhus "ligand presenting assembly" (lpa), verfahren zu dessen herstellung und verwendungen
US7018654B2 (en) * 1999-03-05 2006-03-28 New River Pharmaceuticals Inc. Pharmaceutical composition containing an active agent in an amino acid copolymer structure
US6716452B1 (en) * 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US7060708B2 (en) 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
GB9912911D0 (en) * 1999-06-04 1999-08-04 Zeneca Ltd Chemical process
GB9915074D0 (en) 1999-06-28 1999-08-25 Cortecs Plc Ligand-binding composition
US6774102B1 (en) * 1999-09-29 2004-08-10 Gambro Dialysatoren Gmbh & Co. Kg Extracorporeal endotoxin removal method
US7163918B2 (en) 2000-08-22 2007-01-16 New River Pharmaceuticals Inc. Iodothyronine compositions
US20020099013A1 (en) * 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
AU9063801A (en) * 2000-09-06 2002-03-22 Aventis Pharma Sa Methods and compositions for diseases associated with amyloidosis
DE10048417A1 (de) * 2000-09-29 2002-04-11 Roche Diagnostics Gmbh Verbindungen mit verzweigtem Linker
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
ITMI20011708A1 (it) * 2001-08-03 2003-02-03 Bracco Imaging Spa Coniugati di peptidi, loro derivati con complessi metallici e utilizzo per i'indagine diagnostica tramite imaging per risonanza magnetica(m
US7314956B2 (en) 2001-08-08 2008-01-01 Vaxim, Inc. Multifunctional carrier for the delivery of a pharmacological agent or genetic material into a cell
US20070066537A1 (en) * 2002-02-22 2007-03-22 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US20060014697A1 (en) * 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
US7169752B2 (en) * 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US7375082B2 (en) * 2002-02-22 2008-05-20 Shire Llc Abuse-resistant hydrocodone compounds
US7338939B2 (en) * 2003-09-30 2008-03-04 New River Pharmaceuticals Inc. Abuse-resistant hydrocodone compounds
US7491690B2 (en) 2001-11-14 2009-02-17 Northwestern University Self-assembly and mineralization of peptide-amphiphile nanofibers
US20030229013A1 (en) * 2001-12-07 2003-12-11 Shih-Kwang Wu Solid phase method for synthesis peptide-spacer-lipid conjugates, conjugates synthesized thereby and targeted liposomes containing the same
WO2003070749A2 (en) 2002-02-15 2003-08-28 Northwestern University Self-assembly of peptide-amphiphile nanofibers under physiological conditions
US7700561B2 (en) * 2002-02-22 2010-04-20 Shire Llc Abuse-resistant amphetamine prodrugs
WO2003072735A2 (en) * 2002-02-22 2003-09-04 New River Pharmaceuticals Inc. Use of peptide-drug conjugation to reduce inter-subject variability of drug serum levels
KR100822498B1 (ko) * 2002-02-22 2008-04-16 샤이어 엘엘씨 규제된 물질의 남용을 방지하기 위한 새로운 서방성 약학화합물
US7105486B2 (en) * 2002-02-22 2006-09-12 New River Pharmaceuticals Inc. Abuse-resistant amphetamine compounds
US7659253B2 (en) * 2002-02-22 2010-02-09 Shire Llc Abuse-resistant amphetamine prodrugs
US7554021B2 (en) 2002-11-12 2009-06-30 Northwestern University Composition and method for self-assembly and mineralization of peptide amphiphiles
AU2003298647A1 (en) 2002-11-14 2004-06-15 Claussen, Randal, C. Synthesis and self-assembly of abc triblock bola peptide
US20040101901A1 (en) * 2002-11-27 2004-05-27 Piotr Tabaczewski Novel lipophilic complexes for insertion of receptors into lipid membranes
US20050112087A1 (en) * 2003-04-29 2005-05-26 Musso Gary F. Pharmaceutical formulations for sustained drug delivery
EP1620327B1 (en) * 2003-05-02 2007-02-28 Almar Packaging International Inc. Intermediate bulk container
SI1644019T2 (en) * 2003-05-29 2018-04-30 Shire Llc Abuse resistant amphetamine compounds
US9763977B2 (en) 2003-09-16 2017-09-19 Incube Labs, Llc In vitro bio-reactor circuit
US20050063937A1 (en) * 2003-09-16 2005-03-24 Cheng Li Multiple-arm peptide compounds, methods of manufacture and use in therapy
EA008864B1 (ru) * 2003-09-30 2007-08-31 Нью Ривер Фармасьютикалз Инк. Фармацевтические композиции для предотвращения передозировки или неправильного употребления лекарственных средств
US7544661B2 (en) 2003-12-05 2009-06-09 Northwestern University Self-assembling peptide amphiphiles and related methods for growth factor delivery
EP1696944A4 (en) * 2003-12-05 2008-11-05 Univ Northwestern BRANCHED PEPTIDE AMPHIPHILES, RELATED EPITOPES COMPOUNDS AND SELF-ASSOCIATED STRUCTURES THEREOF
GB0408164D0 (en) * 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
WO2006096614A2 (en) 2005-03-04 2006-09-14 Northwestern University Angiogenic heparin binding peptide amphiphiles
US7964200B2 (en) 2005-05-18 2011-06-21 Children's Hospital & Research Center At Oakland Methods and compositions for immunizing against Chlamydia infection
WO2007027954A2 (en) * 2005-08-30 2007-03-08 Children's Hospital & Research Center At Oakland Methods for identifying an epitope of a polypeptide, chlamydial antigenic polypeptides identified thereby, and methods of use thereof
US8076295B2 (en) 2007-04-17 2011-12-13 Nanotope, Inc. Peptide amphiphiles having improved solubility and methods of using same
WO2009146885A2 (en) * 2008-06-02 2009-12-10 Spiderbiotech S.R.L. Lipidated antibacterial peptides
US8637040B2 (en) * 2008-09-21 2014-01-28 National Institute of Health (NIH), U.S. Dept. of Health and Human Services (DHHS) Genus-wide chlamydial peptide vaccine antigens
WO2010111652A2 (en) * 2009-03-27 2010-09-30 Kansas State University Research Foundation Branched amphipathic oligo-peptides that self-assemble into vesicles
MX2011010780A (es) 2009-04-13 2011-10-28 Univ Northwestern Andamios novedosos basados en peptido para la regeneracion de cartilagos y metodos para su uso.
WO2014026033A1 (en) 2012-08-08 2014-02-13 University Of Florida Research Foundation, Inc. Cross-reactive t cell epitopes of hiv, siv, and fiv for vaccines in humans and cats
US20140275478A1 (en) * 2013-03-18 2014-09-18 Statens Serum Institut Vaccines against Chlamydia sp.
AU2014356912B2 (en) * 2013-12-01 2019-08-01 University Of Copenhagen Fatty acid derivatives of dimeric inhibitors of PSD-95
AU2016349937B2 (en) * 2015-11-04 2021-09-30 University Of The Sunshine Coast Chlamydia antigens and uses thereof
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520558D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
US11560419B2 (en) * 2018-12-21 2023-01-24 West Virginia University Targeting tumor microenvironments with recombinant prokaryotic collagen-like proteins
CN118121547B (zh) * 2024-03-06 2024-10-01 西南大学 一种多肽导向分子嵌入式脂质复合物及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1052699A (es) * 1963-12-03
GB2217319A (en) * 1988-04-19 1989-10-25 Synpharm Ltd Racemic and optically active fatty amino acids, their homo- abd hetero-oligomers and conjugates, the process of their production, their pharmaceutical composi
GB8812214D0 (en) * 1988-05-24 1988-06-29 Hoffmann La Roche Use of peptide from circumsporozoite protein of p falciparum as universally recognized t-cell epitope

Also Published As

Publication number Publication date
DE69315842D1 (de) 1998-01-29
US5882645A (en) 1999-03-16
WO1994002506A1 (en) 1994-02-03
AU4715493A (en) 1994-02-14
GB9215780D0 (en) 1992-09-09
EP0652896B1 (en) 1997-12-17
DE69315842T2 (de) 1998-04-09
EP0652896A1 (en) 1995-05-17

Similar Documents

Publication Publication Date Title
ES2111167T3 (es) Compuestos peptidicos.
ATE290014T1 (de) Festphasen-peptidsynthese
ES2146212T3 (es) Proteinas de union a antigenos trivalentes monoespecificas.
ES2124276T3 (es) Anticuerpos perfeccionados contra plasmodium falciparum.
ATE475675T1 (de) Verwendung prokariotischer pest-ähnlicher peptide zur verstärkung der immunogenität von antigenen
ES2185631T3 (es) Vacunas de clostridium perfringens.
ES2010538A6 (es) Procedimiento para la preparacion de un gen sintetico.
AR017866A1 (es) Metodo para incrementar las inmunorespuestas de vacunas de acidos nucleicos, composiciones farmaceuticas de aplicacion en dicho metodo, procedimientopara preparar dichas composiciones y vacunas utilizadas en dicho metodo.
DK0489968T3 (da) Syntetiske antigener til påvisning af antistoffer imod hepatitis C virus
BR9809656A (pt) Composição imunopotencializante
DK124087D0 (da) Immunogent peptidantigen svarende til plasmodium vivax circumsporozoitprotein
ES2194836T3 (es) Peptidos para su uso en vacunacion e induccion de anticuerpos neutralizantes contra el virus de la inmunodeficiencia humana.
IT8319160A0 (it) Procedimento di sintesi di peptidi e agenti di bloccaggio di amminoacidi.
WO2004030616A3 (en) Ii-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES
ES2185628T3 (es) Procedimiento para preparar proteinas modificadas.
FR2692282B1 (fr) Clonage du gene codant pour la proteine gp28.5 de t. gondii; fragments peptidiques issus de ladite proteine et leurs applications.
ES549185A0 (es) Procedimiento para sintetizar peptidos a partir de aminoaci-dos
ES8702438A1 (es) Un metodo para preparar un peptido
ES2042461T1 (es) Producto y procedimiento para el te\ido oxidativo del cabello.
DK1621547T3 (da) Konjugater af polypeptidmolekyler og lipider fra malarie præ-erythrocytisk stadie
ES2083387T3 (es) Peptidos sinteticos y sus mezclas para la deteccion de anticuerpos hiv.
IT1249684B (it) Epitopi della proteina env del virus dell'epatite c.
ATE356867T1 (de) Epitopen aus dem epha2-antigen
ATE31418T1 (de) Arzneimittel, welche tripeptide enthalten.
PE20010239A1 (es) Gen derivado de lawsonia y polipeptidos, peptidos y proteinas de hemolisina relacionados y sus usos

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 652896

Country of ref document: ES